Literature DB >> 12930976

mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity.

Dieter Hüsken1, Fred Asselbergs, Bernd Kinzel, Francois Natt, Jan Weiler, Pierre Martin, Robert Häner, Jonathan Hall.   

Abstract

A cellular assay has been developed to allow measurement of the inhibitory activity of large numbers of oligonucleotides at the protein level. The assay is centred on an mRNA fusion transcript construct comprising of a full-length reporter gene with a target region of interest inserted into the 3'-untranslated region. Luciferase and fluorescent reporter genes were used in the constructs. The insert can be from multiple sources (uncharacterised ESTs, partial or full-length genes, genes from alternate species, etc.). Large numbers of oligonucleotides were screened for antisense activity against a number of such constructs bearing different reporters, in different cell lines and the inhibitory profiles obtained were compared with those observed through screening the oligonucleotides against the corresponding endogenous genes assayed at the mRNA level. A high degree of similarity in the profiles was obtained indicating that the fusion constructs are suitable surrogates for the endogenous messages for characterisation of antisense oligonucleotides (ASOs). Furthermore, the results support the hypothesis that the secondary structure of mRNAs are divided into domains, the nature of which is determined by primary nucleotide sequence. Oligonucleotides whose activity is dependent on the local structure of their target mRNAs (e.g. ASOs, short interfering RNAs) can be characterised via such fusion RNA constructs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930976      PMCID: PMC212822          DOI: 10.1093/nar/gng103

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  43 in total

1.  Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances.

Authors:  U Baron; H Bujard
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Selection of antisense oligodeoxynucleotides against glutathione S-transferase Mu.

Authors:  Peter A C 't Hoen; Ruud Out; Jan N M Commandeur; Nico P E Vermeulen; F H D van Batenburg; Muthiah Manoharan; Theo J C van Berkel; Erik A L Biessen; Martin K Bijsterbosch
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

Review 3.  Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy.

Authors:  Thomas Tuschl; Arndt Borkhardt
Journal:  Mol Interv       Date:  2002-06

Review 4.  Antisense RNA and DNA.

Authors:  H M Weintraub
Journal:  Sci Am       Date:  1990-01       Impact factor: 2.142

5.  Substrate sequence effects on "hammerhead" RNA catalytic efficiency.

Authors:  M J Fedor; O C Uhlenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 6.  Molecular mechanisms of antisense drugs: RNase H.

Authors:  S T Crooke
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1998-04

7.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways.

Authors:  Dianne S Schwarz; György Hutvágner; Benjamin Haley; Phillip D Zamore
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

8.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

9.  Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor.

Authors:  Torgeir Holen; Mohammed Amarzguioui; Merete T Wiiger; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

Review 10.  Antisense and/or immunostimulatory oligonucleotide therapeutics.

Authors:  S Agrawal; E R Kandimalla
Journal:  Curr Cancer Drug Targets       Date:  2001-11       Impact factor: 3.428

View more
  7 in total

Review 1.  Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Vision Res       Date:  2007-10-31       Impact factor: 1.886

2.  A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.

Authors:  Edwin H Yau; Mark C Butler; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2016-05-25       Impact factor: 3.467

3.  Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference.

Authors:  Deepak R Thakker; Francois Natt; Dieter Hüsken; Rainer Maier; Matthias Müller; Herman van der Putten; Daniel Hoyer; John F Cryan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

4.  A modified RMCE-compatible Rosa26 locus for the expression of transgenes from exogenous promoters.

Authors:  Jan S Tchorz; Thomas Suply; Iwona Ksiazek; Claudio Giachino; Dimitri Cloëtta; Claus-Peter Danzer; Thierry Doll; Andrea Isken; Marianne Lemaistre; Verdon Taylor; Bernhard Bettler; Bernd Kinzel; Matthias Mueller
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

5.  Improved nucleic acid descriptors for siRNA efficacy prediction.

Authors:  Simone Sciabola; Qing Cao; Modesto Orozco; Ignacio Faustino; Robert V Stanton
Journal:  Nucleic Acids Res       Date:  2012-12-14       Impact factor: 16.971

6.  Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.

Authors:  Anne Dallas; Svetlana V Balatskaya; Tai-Chih Kuo; Heini Ilves; Alexander V Vlassov; Roger L Kaspar; Kevin O Kisich; Sergei A Kazakov; Brian H Johnston
Journal:  Nucleic Acids Res       Date:  2008-10-25       Impact factor: 16.971

7.  Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.

Authors:  Luca F R Gebert; Mario A E Rebhan; Silvia E M Crivelli; Rémy Denzler; Markus Stoffel; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2013-09-24       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.